CN101756961A - 含有长链和中链甘油三酯的药物制剂 - Google Patents

含有长链和中链甘油三酯的药物制剂 Download PDF

Info

Publication number
CN101756961A
CN101756961A CN200910176277A CN200910176277A CN101756961A CN 101756961 A CN101756961 A CN 101756961A CN 200910176277 A CN200910176277 A CN 200910176277A CN 200910176277 A CN200910176277 A CN 200910176277A CN 101756961 A CN101756961 A CN 101756961A
Authority
CN
China
Prior art keywords
pharmaceutical composition
oil
aag
chain triglyceride
long chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN200910176277A
Other languages
English (en)
Chinese (zh)
Inventor
埃德加·H·厄尔马
罗伯特·曼斯菲尔德
马库斯·贝姆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Conforma Therapeutics Corp
Original Assignee
Conforma Therapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2003/010533 external-priority patent/WO2003086381A1/fr
Application filed by Conforma Therapeutics Corp filed Critical Conforma Therapeutics Corp
Publication of CN101756961A publication Critical patent/CN101756961A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Biophysics (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN200910176277A 2003-03-13 2003-10-04 含有长链和中链甘油三酯的药物制剂 Pending CN101756961A (zh)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US45481203P 2003-03-13 2003-03-13
US60/454,812 2003-03-13
USPCT/US03/10533 2003-04-04
PCT/US2003/010533 WO2003086381A1 (fr) 2002-04-10 2003-04-04 Formulations d'ansamycine et procedes de production et d'utilisation de celles-ci
US47843003P 2003-06-12 2003-06-12
US60/478,430 2003-06-12
US49105003P 2003-07-29 2003-07-29
US60/491,050 2003-07-29

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN 200380110249 Division CN1764446A (zh) 2003-03-13 2003-10-04 含有长链和中链甘油三酯的药物制剂

Publications (1)

Publication Number Publication Date
CN101756961A true CN101756961A (zh) 2010-06-30

Family

ID=35351739

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200910176277A Pending CN101756961A (zh) 2003-03-13 2003-10-04 含有长链和中链甘油三酯的药物制剂

Country Status (6)

Country Link
EP (1) EP1605931A4 (fr)
JP (1) JP2006514994A (fr)
CN (1) CN101756961A (fr)
AU (1) AU2003277299B2 (fr)
CA (1) CA2518836A1 (fr)
WO (1) WO2004082676A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106018611A (zh) * 2016-06-21 2016-10-12 广州白云山汉方现代药业有限公司 一种气相色谱内标法检测中链甘油三酯含量的测定方法

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0418147A (pt) 2003-12-23 2007-04-17 Infinity Pharmaceuticals Inc análogos de ansamicinas contendo benzoquinona e seus métodos de uso
EP2298748B1 (fr) 2004-11-18 2016-07-20 Synta Pharmaceuticals Corp. Composés triazole modulant l'activité de HSP90
JP2008531708A (ja) * 2005-02-28 2008-08-14 コーザン バイオサイエンシス インコーポレイテッド １７−アリルアミノ−１７−デメトキシゲルダナマイシンを含有する医薬製剤
JP2008535844A (ja) * 2005-04-07 2008-09-04 コンフォーマ・セラピューティクス・コーポレイション リン脂質をベースとする医薬製剤およびその製造および使用方法
JP2008539265A (ja) 2005-04-29 2008-11-13 コーザン バイオサイエンシス インコーポレイテッド １７−ａａｇ又は１７−ａｇ又はどちらかのプロドラッグを使用する多発性骨髄腫の治療方法
EP1928846B1 (fr) 2005-08-18 2014-06-04 Synta Pharmaceuticals Corp. Dérivés de triazole modulant l'activité de hsp90
AU2006320435A1 (en) * 2005-12-01 2007-06-07 Conforma Therapeutics Corporation Compositions containing ansamycin
PE20081506A1 (es) 2006-12-12 2008-12-09 Infinity Discovery Inc Formulaciones de ansamicina
WO2010045442A1 (fr) 2008-10-15 2010-04-22 Infinity Discovery, Inc. Compositions d'ansamycine hydroquinone
BR112012003263A2 (pt) 2009-08-14 2015-09-22 Opko Health Inc formulações intravenosas de antagonistas de neuroquinina-1
EP2560640A1 (fr) 2010-04-19 2013-02-27 Synta Pharmaceuticals Corp. Thérapie anticancéreuse à l'aide d'une combinaison d'un composé inhibiteur de hsp90 et d'un inhibiteur d'egfr
WO2013067162A1 (fr) 2011-11-02 2013-05-10 Synta Pharmaceuticals Corp. Thérapie anticancéreuse utilisant une combinaison d'inhibiteurs de hsp 90 et d'inhibiteurs de topoisomérase i
JP2014534228A (ja) 2011-11-02 2014-12-18 シンタ ファーマシューティカルズ コーポレーション 白金含有剤とｈｓｐ９０阻害剤の組合せ療法
EP2780010A1 (fr) 2011-11-14 2014-09-24 Synta Pharmaceuticals Corp. Association thérapeutique d'inhibiteurs de hsp90 et d'inhibiteurs de braf

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995001342A1 (fr) * 1993-06-29 1995-01-12 Pfizer Inc. Derives de l'ansamycine utilises comme agents anti-oncogenes et anticancereux
US5932566A (en) * 1994-06-16 1999-08-03 Pfizer Inc. Ansamycin derivatives as antioncogene and anticancer agents
US6140374A (en) * 1998-10-23 2000-10-31 Abbott Laboratories Propofol composition
DE10036871A1 (de) * 2000-07-28 2002-02-14 Pharmasol Gmbh Dispersionen zur Formulierung wenig oder schwer löslicher Wirkstoffe
JP2005528390A (ja) * 2002-04-10 2005-09-22 コンフォーマ・セラピューティクス・コーポレイション アンサマイシン製剤およびその製造ならびに使用方法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106018611A (zh) * 2016-06-21 2016-10-12 广州白云山汉方现代药业有限公司 一种气相色谱内标法检测中链甘油三酯含量的测定方法

Also Published As

Publication number Publication date
AU2003277299B2 (en) 2009-12-10
EP1605931A4 (fr) 2009-04-29
JP2006514994A (ja) 2006-05-18
WO2004082676A1 (fr) 2004-09-30
AU2003277299A1 (en) 2004-10-11
EP1605931A1 (fr) 2005-12-21
CA2518836A1 (fr) 2004-09-30

Similar Documents

Publication Publication Date Title
US7060285B2 (en) Dispersions for the formulation of slightly or poorly soluble agents
Talegaonkar et al. Microemulsions: a novel approach to enhanced drug delivery
US6682758B1 (en) Water-insoluble drug delivery system
US20100063020A1 (en) Oral pharmaceutical formulations and methods for producing and using same
US20110275705A1 (en) Stable injectable oil-in-water docetaxel nanoemulsion
AU2003277299B2 (en) Drug formulations having long and medium chain triglycerides
US20090238880A1 (en) Phospholipid-based pharmaceutical formulations and methods for producing and using same
US20060148776A1 (en) Drug formulations having long and medium chain triglycerides
ES2321912T3 (es) Formulaciones en nanoparticulas de fenofibrato.
AU2011287955A1 (en) Pharmaceutical dosage form comprising 6'-fluoro-(N-methyl- or N,N-dimethyl-)-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine for the treatment of neuropathic pain
AU2003226285B2 (en) Ansamycin formulations and methods for producing and using same
WO2012016703A2 (fr) Forme galénique pharmaceutique comprenant 6'-fluoro-(n-méthyl- or n,n-diméthyl-)-4-phényl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine
CN101390851A (zh) 双环醇含表面活性剂的药物组合物及其制剂
US8481589B2 (en) Taxoid-based compositions
US20070129342A1 (en) Compositions Containing Ansamycin
CN1764446A (zh) 含有长链和中链甘油三酯的药物制剂
HK1089972A (en) Drug formulations having long and medium chain triglycerides
EP3917498A1 (fr) Composition pharmaceutique auto-émulsifiante sous forme liquide, contenant comme substance active une substance médicamenteuse instable dans un environnement aqueux

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20100630